Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cistron Biotechnology(CIST)$.30 -- Ignore unavailable to you. Want to Upgrade?

To: Andrew who wrote (2449)	8/27/1999 5:08:00 PM
From: Walter Morton	Respond to of 2742

Most people don't sell there stock if they expect it to appreciate. That may explain the low volume.

To: Andrew who wrote (2449)	8/27/1999 7:17:00 PM
From: John Metcalf	Read Replies (1) \| Respond to of 2742

It is not likely that information would leak from Genome Securities. They are a three-person firm in Scranton, PA. There will be offers for Cistron, because they have 8 figures in cash. Someone will at least offer the cash value, in order to get CIST's patents, royalties (tiny) and HMR deal potential for free. A cash-strapped company might acquire CIST for stock at current value, which would be equivalent to selling shares without discount. Yes, there will be offers.

To: Andrew who wrote (2449)	8/28/1999 4:27:00 AM
From: Walter Morton	Respond to of 2742

Do you think CIST is using this news as leverage in the negotiations: Message 11093067

To: Andrew who wrote (2449)	9/28/1999 11:54:00 PM
From: Walter Morton	Respond to of 2742

<<anticipates that there will be a further reduction of employees>> It looks like severance pay is going to be an issue again next year.